Invest in Avantium Chemicals
Our strategy has three pillars:-
Progress our YXY technology, to produce green building blocks. These building blocks are the smallest parts that enable the transition from the oil-based economy to a green and sustainable world. The process converts biomass into furanics. YXY feeds a green economy by delivering on both price and performance. We plan to exploit the commercial value of the YXY technology by licensing it to market leaders and challengers.
-
Continue to grow our profitable high-throughput services & systems business, in the area of catalysis research. Our customer base contains industry leaders in the chemical, refinery and petrochemical industries, including Shell, Sasol, BP, PetroBras, IFP and Celanese.
-
Continue to expand our enhanced high-throughput technology platform, on which we have successfully developed our YXY technology and built our services & systems business. Investing in Avantium is investing in a breakthrough process to produce a range of green products that compete on price and performance.
For more information please contact Frank Roerink, CFO Avantium (frank.roerink@avantium.com)
Invest in Avantium Pharma
Avantium announced the intention to create a stand-alone pharmaceutical company in December 2009. Avantium Pharma has an excellent technological position and expertise in solid state research including crystallization and is a provider of services & systems equipment in this area. The technology forms a strong platform for our development program focused on ‘unlocking’ new forms and formulations of currently marketed products through crystal engineering technology. Avantium Pharma strives to improve product efficacy, reduce side-effects and patient compliance through these new formulations and this is often possible to achieve through an accelerated clinical development programme.
Our strategy
Our strategy is to progress our development programs and exploit the commercial value of our expanding patent portfolio by securing value-adding partnerships, while at the same time continuing to expand our services and systems business.
Avantium Pharma is seeking to raise finance to spin the business out as a separate company.
For more information contact Gunnar Staaf, CEO Avantium Pharma (gunnar.staaf@avantium.com)
Investor Relations
Avantium is a leading technology company in the area of advanced high-throughput R&D with a focus on applications in the energy, chemicals and pharmaceutical industries.
Shareholders
Avantium has a unique international shareholder base. The following venture capital providers support our business:
Aescap Venture (Amsterdam, the Netherlands )
Alpinvest (Amsterdam, the Netherlands)
Capricorn Cleantech Fund (Leuven, Belgium)
DFJ Esprit (London, UK)
EDB Investments (Singapore)
ING Group (Amsterdam, the Netherlands)
Navitas Capital (Bilthoven, the Netherlands)